# A Study to Compare the Macitentan-tadalafil Fixed Dose Combination Tablet Relative to the Concomitant Administration of the Reference Tablets of Macitentan and Tadalafil in Healthy Subjects

> **NCT03215966** · PHASE1 · COMPLETED · sponsor: **Actelion** · enrollment: 38 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **COMBINATION_PRODUCT:** Macitentan / tadalafil FDC
- **DRUG:** Macitentan (Opsumit®)
- **DRUG:** Tadalafil (Adcirca®)

## Key facts

- **NCT ID:** NCT03215966
- **Lead sponsor:** Actelion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-07
- **Primary completion:** 2017-09-24
- **Final completion:** 2017-09-24
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2025-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03215966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03215966, "A Study to Compare the Macitentan-tadalafil Fixed Dose Combination Tablet Relative to the Concomitant Administration of the Reference Tablets of Macitentan and Tadalafil in Healthy Subjects". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03215966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*